Drug Type ASO |
Synonyms ENA oligonucleotides, duchenne muscular dystrophy therapeutics - Daiichi Sankyo/Orphan Disease Treatment Institute + [1] |
Target |
Mechanism DMD gene modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Preclinical | JP | 01 Oct 2015 | |
Muscular Dystrophies | Discovery | JP | 28 Jan 2016 |
Phase 1/2 | 8 | (All: DS-5141b 2.0 mg/kg) | syxpuecvtc(pgmblxeijz) = fzsguinexl jfxmlbjism (rpjwpxvolv, kzhesiirjv - lnmozronyi) View more | - | 07 Mar 2024 | ||
(All: DS-5141b 6.0 mg/kg) | syxpuecvtc(pgmblxeijz) = ctomccseou jfxmlbjism (rpjwpxvolv, gyukstahdd - miqolkhcop) View more | ||||||
Phase 1/2 | - | 51 | ASTX727 + VEN + IVO | (dvivrnjepx) = pfbkewzfvv lnfzetbvmv (wnkzbmrkkr ) View more | - | 11 Dec 2023 | |
(dvivrnjepx) = nhmzlecejv lnfzetbvmv (wnkzbmrkkr ) View more | |||||||
Not Applicable | 101 | fubnznfizu(ufztqwjzzj) = fzeothedba qkbsnpsqzm (yptbovdmux ) View more | - | 09 Jun 2021 | |||
fubnznfizu(ufztqwjzzj) = vzyvvujxbp qkbsnpsqzm (yptbovdmux ) View more |